ERA PerMed is an ERA-NET Cofund, supported by 32 partners of 23 countries and cofunded by the European Commission (EC). To align national research strategies, promote excellence, reinforce the competitiveness of European players in Personalised Medicine (PM), and enhance the European collaboration with non-EU countries, 33 funding organisations have agreed to launch the fifth Joint Transnational Call for collaborative innovative research projects in PM. This represents the fourth additional call non-cofunded by the EC. The funding organisations participating in this call particularly wish to promote innovative interdisciplinary collaboration and to encourage translational research proposals.
Aims of the Call
With its fifth transnational call (non-cofunded by the EC), ERA PerMed aims to foster research in prevention in personalised medicine. The overarching goal of the call is the development of tailor-made strategies for prevention of disease and disease progression, at three different levels:
i. preventive measures decreasing the rate of incidence (primary prevention),
ii. early detection to increase the efficacy of a preventive therapy, even before symptoms are developed (secondary prevention), and
iii. interventions preventing disease recurrence or improving patients’ care and quality of life (tertiary prevention).
Research on prevention from over-treatment or overmedicalisation in primary, secondary and tertiary personalised preventive approaches is optional and could be part of research proposals, if applicable.
The clinical relevance of the proposed PM approach needs to be convincingly demonstrated.
The overall objectives of the ERA PerMed call are to:
- Support translational research projects in the field of personalised medicine;
- Encourage and enable interdisciplinary collaborations towards implementation of PM, in combining pre-clinical or clinical research with bio-informatics components as well as ELSA research or implementation research, including health economics;
- Encourage collaboration between academia (research teams from universities, higher education institutions, public research institutions, research centres), clinical/public health research (research teams from hospital/ public health, healthcare settings and other healthcare organisations), private partners e.g. SMEs (small and medium-sized enterprises) as well as policy makers, regulatory/HTA agencies and patient organisations.
As Personalised Medicine is non-disease-specific, but rather an overall approach that can be adopted and adapted to a multiplicity of medical conditions, research projects in every disease entity are encouraged. The involvement of partners with the respective expertise in the consortium is required.
Scope of the Call
The JTC2022 is constructed around the following three research areas in order to ensure the development of specific PM approaches considering the major aspects needed for their successful implementation in the health systems: (1) “Translating Basic to Clinical Research and Beyond”, (2) “Data and Information and Communication Technology (ICT)” and (3) “Responsible and Effective Implementation in Healthcare”.
Each proposal MUST address at least one module out of each research area:
Assessment of the coherent integration and combination of the different research areas and modules in the proposals is part of the evaluation process.
If you are looking for potential partners, please have a look at the ICPerMed Partnering Tool
View full Call text on ERA PER MED website
- The FNR supports this Call with 300,000 EUR.
- Overall budget for this Call is approx. 29 MEUR
In addition to submitting at ERA PerMed, Luxembourg applicants must also submit the proposal – along with the FNR INTER documents – to the FNR no later than 7 working days after the ERA PerMed deadline(s).
- Opening of online submission tool: 1 December 2021
- Submission deadline for pre-proposals: 17 February, 17:00 CET
- Submission deadline for full-proposals: 14 June 2022, 17:00 CET